株式会社極東書店トップ商品一覧Biolust, Brain Death, and the Battle Over Organ Transplants : America's Biotech Juggernaut and its Japanese Critics. Ed. by E. R. Drott.

商品詳細

Biolust, Brain Death, and the Battle Over Organ Transplants

Biolust, Brain Death, and the Battle Over Organ Transplants : America's Biotech Juggernaut and its Japanese Critics. Ed. by E. R. Drott.

・ISBN 978-1-350-25499-2 2022 hard GB£ 90.00

[在庫] ¥28,512.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り

・ISBN 978-1-350-25507-4 2024 paper GB£ 29.99

¥9,500.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り

電子版あり 大学・学術機関向け電子ブック(eBook)ISBN 978-1-350-25502-9

著者・編者LaFleur, William R., / Ed. by E. R. Drott
出版社(Bloomsbury Academic, UK)
出版年月2022.12
ページ数262 pp.
言語ENG
ニュース番号<684-1090 684-615>

解説

William LaFleur (1936-2010), an eminent scholar of Japanese studies, left behind a substantial number of influential publications, as well as several unpublished works. The most significant of these examines debates concerning the practice of organ transplantation in Japan and the United States, and is published here for the first time.
This provocative book challenges the North American medical and bioethical consensus that considers the transplantation of organs from brain dead donors as an unalloyed good. It joins a growing chorus of voices that question the assumption that brain death can be equated facilely with death. It provides a deep investigation of debates in Japan, introducing numerous Japanese bioethicists whose work has never been treated in English. It also provides a history of similar debates in the United States, problematizing the commonly held view that the American public was quick and eager to accept the redefinition of death.
A work of intellectual and social history, this book also directly engages with questions that grow ever more relevant as the technologies we develop to extend life continue to advance. While the benefits of these technologies are obvious, their costs are often more difficult to articulate. Calling attention to the risks associated with our current biotech trajectory, LaFleur stakes out a highly original position that does not fall neatly onto either side of contemporary US ideological divides.